Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), in which most patients exhibit non-progressive, non-alcoholic fatty liver (NAFL) attributable to simple steatosis. Multiple hits, including genetic differences, fat accumulation, insulin resistance and intestinal microbiota changes, account for the progression of NASH. NAFLD is strongly associated with obesity, which induces adipokine secretion, endoplasmic reticulum (ER) and oxidative stress at the cellular level, which in turn induces hepatic steatosis, inflammation and fibrosis. Among these factors, gut microbiota are acknowledged as having an important role in initiating this multifactorial disease. Oxidative stress is considered to be a key contributor in the progression from NAFL to NASH. Macrophage infiltration is apparent in NAFL and NASH, while T-cell infiltration is apparent in NASH. Although several clinical trials have shown that antioxidative therapy with vitamin E can effectively control hepatitis pathology in the short term, the long-term effects remain obscure and have often proved to be ineffective in many other diseases. Several long-term antioxidant protocols have failed to reduce mortality. New treatment modalities that incorporate current understanding of NAFLD molecular pathogenesis must be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 1×
“is being investigated as a cancer treatment in several clinical trials [114].”
BackgroundCani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819 · cited 1×
“Plasma endotoxin levels are significantly higher in patients with NAFLD and in murine NASH models [27,28].”
BackgroundGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“Keywords: non-alcoholic fatty liver; non-alcoholic steatohepatitis; microbiome; oxidative stress”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“years, but increases insulin resistance and plasma triglyceride levels [109].”
BackgroundCani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D. M., et al. (2009) · Gut · doi:10.1136/gut.2008.165886 · Cited by 2,518 · cited 1×
“The intestinal microbiota of diabetic mice can be altered with prebiotic supplementation to increase Bifidobacterium, Lactobacillus and Clostridium coccoides, thereby producing lower plasma LPS and cytokine levels, and decreased hepatic expression of inflammatory and oxidative stress markers [30].”
BackgroundInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 2×
“However, an inflammasome-deficient mouse model developed exacerbated hepatic steatosis and inflammation through the influx of TLR4 and TLR9 agonists into the portal vein [34].”
BackgroundNishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.1964 · Cited by 2,230
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5
Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010) · Science · doi:10.1126/science.1179721 · Cited by 2,068
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434 · cited 2×
“Patients with biopsy-proven NAFLD have increased intestinal permeability with disrupted intercellular tight junctions in the intestine [28].”
BackgroundMetabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network
Scarpulla, R. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.09.019 · Cited by 1,281
The sites and topology of mitochondrial superoxide production
Brand, M. D. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.01.003 · Cited by 1,217 · cited 1×
“Under physiological conditions, the majority of incompletely reduced ROS, such as superoxide, are detoxified into water and steady-state oxidant concentrations are maintained at relatively low levels (less than 1% of total oxygen consumed by mitochondria) by a variety of antioxidant defenses and repair enzymes [79].”
BackgroundInteractions Between the Intestinal Microbiome and Liver Diseases
Schnabl, B., & Brenner, D. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.020 · Cited by 971 · cited 1×
“fasting-induced adipocyte factor (Fiaf), resulting in increased activity of lipoprotein lipase (LPL) and increased triglyceride accumulation in the liver, which indicates a direct influence of the microbiome on NAFLD [33].”
BackgroundRole of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955 · cited 1×
“The non-parenchymal cells in the liver, such as Kupffer cells and HSC, play significant roles in the progression of chronic liver inflammation and fibrosis progression [86].”
BackgroundBeyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.-I., Matsuda, K., Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., et al. (2013) · Nature · doi:10.1038/nature12656 · Cited by 757 · cited 1×
“The adiponectin receptor agonist AdipoRon is considered to be a new treatment candidate for type 2 diabetes [139].”
BackgroundIntestinal microbiota in patients with nonalcoholic fatty liver disease
Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., McGilvray, I. D., & Allard, J. P. (2013) · Hepatology · doi:10.1002/hep.26319 · Cited by 749 · cited 1×
“In human NAFLD stool, Clostridium coccoides has been shown to be higher in NASH, while Bacteroides/Prevotella is lower in NASH [32].”
BackgroundHernández–Gea, V., Ghiassi–Nejad, Z., Rozenfeld, R., Gordon, R., Fiel, M. I., Yue, Z., Czaja, M. J., & Friedman, S. L. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.044 · Cited by 654
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011) · Hepatology · doi:10.1002/hep.24341 · Cited by 645
Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells
Glass, C. K., & Saijo, K. (2010) · Nature Reviews Immunology · doi:10.1038/nri2748 · Cited by 619 · cited 3×
“Inflammatory pathways in macrophages are under strict control by several transcription factors such as NF-kB, AP1, the peroxisome proliferator-activated receptor (PPAR) family, LXR, and associated coactivating and coregulatory molecules.”
BackgroundInfluentialGoodpaster, B. H., DeLany, J. P., Otto, A. D., Kuller, L., Vockley, J., South-Paul, J. E., Thomas, S. B., Brown, J., McTigue, K., Hames, K. C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1505 · Cited by 558
The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease
Gadd, V. L., Skoien, R., Powell, E. E., Fagan, K. J., Winterford, C., Horsfall, L., Irvine, K., & Clouston, A. D. (2014) · Hepatology · doi:10.1002/hep.26937 · Cited by 452
Hepatic stellate cell lipid droplets: A specialized lipid droplet for retinoid storage
Blaner, W. S., O'Byrne, S. M., Wongsiriroj, N., Kluwe, J., D'Ambrosio, D. M., Jiang, H., Schwabe, R. F., Hillman, E. M. C., Piantedosi, R., & Libien, J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.11.001 · Cited by 444
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Development of the human gastrointestinal microbiota and insights from high-throughput sequencing
Dominguez-Bello, M. G., Blaser, M. J., Ley, R. E., & Knight, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.011 · Cited by 405
Hong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385
Leuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T. (2010) · Hepatology · doi:10.1002/hep.23727 · Cited by 317 · cited 1×
“found improvements in ALT but not in liver histology, even at high doses [126].”
BackgroundTomita, K., Teratani, T., Suzuki, T., Shimizu, M., Sato, H., Narimatsu, K., Okada, Y., Kurihara, C., Irie, R., Yokoyama, H., et al. (2014) · Hepatology · doi:10.1002/hep.26604 · Cited by 315 · cited 13×
“The increased expression of TLR4 sensitizes cells to TGF-β-induced activation [100].”
BackgroundInfluentialLeroux, A., Ferrere, G., Godie, V., Cailleux, F., Renoud, M.-L., Gaudin, F., Naveau, S., Prévot, S., Makhzami, S., Perlemuter, G., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.028 · Cited by 246
Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy
Hernández-Gea, V., Hilscher, M., Rozenfeld, R., Lim, M. P., Nieto, N., Werner, S., Devi, L. A., & Friedman, S. L. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.016 · Cited by 236 · cited 1×
“ER stress in HSCs results in increased autophagy and HSC activation to fibrogenic status [88].”
BackgroundCuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226 · cited 1×
“A GLP-1 receptor agonist in type 2 diabetic patients with NAFLD caused a reduction in intrahepatic lipid content that correlated with diabetic control [118].”
BackgroundMusso, G., Cassader, M., De Michieli, F., Rosina, F., Orlandi, F., & Gambino, R. (2012) · Hepatology · doi:10.1002/hep.25739 · Cited by 126 · cited 1×
“function in patients with NASH, but not in those with simple steatosis [45].”
BackgroundXia, Y., Li, Q., Zhong, W., Dong, J., Wang, Z., & Wang, C. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-31 · Cited by 53
Cited by
The role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Oxidative stress in obesity: A critical component in human diseases
Marseglia, L., Manti, S., D’Angelo, G., Nicotera, A., Parisi, E., Di Rosa, G., Gitto, E., & Arrigo, T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010378 · Cited by 933
Non-alcoholic fatty liver disease and dyslipidemia: An update
Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.003 · Cited by 564
Tsurusaki, S., Tsuchiya, Y., Koumura, T., Nakasone, M., Sakamoto, T., Matsuoka, M., Imai, H., Yuet-Yin Kok, C., Okochi, H., Nakano, H., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1678-y · Cited by 529
Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity · doi:10.1002/oby.22344 · Cited by 257
“Exploratory objectives included assessing effects of pegbelfermin on plasma lipids, total adiponectin, serum PRO-C3, chitinase3-like protein 1 (CHI3L1, also known as YKL-40), a biomarker of liver fibrosis (14), and plasminogen activation inhibitor-1 (PAI-1), a NASH biomarker (15).”
BackgroundInfluential
Metadata
- Authors
- Takaki, A., Kawai, D., & Yamamoto, K.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2014-04-29
- Volume
- 15
- Issue
- 5
- Pages
- 7352-7379
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2055308091
- Cited by
- 126
- References
- 35
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.